According to TipRanks.com, Hill is a 5-star analyst with an average return of 7.3% and a 55.2% success rate. Hill covers the Healthcare sector, focusing on stocks such as AmerisourceBergen, Molina Healthcare, and 1Life Healthcare.
Currently, the analyst consensus on Humana is a Moderate Buy with an average price target of $512.92, a 4.0% upside from current levels. In a report issued on July 14, Truist Financial also maintained a Hold rating on the stock with a $550.00 price target.
Based on Humana’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $23.97 billion and net profit of $930 million. In comparison, last year the company earned revenue of $20.67 billion and had a net profit of $828 million.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HUM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humana Inc. is a leading health insurance service provider in the United States. The company, through its Retail division, provides medicare benefits and state-based medicaid contracts, which are marketed on a retail basis to individuals. The Group and Specialty business offers employer group commercial fully-insured medical products and specialty health insurance benefits. Humana offers pharmacy solutions, provider services, home-based services, and clinical programs to the company’s health plan members as well as to third parties through the Healthcare Services segment.
Read More on HUM: